{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T20:07:14Z","timestamp":1781467634198,"version":"3.54.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,24]],"date-time":"2020-10-24T00:00:00Z","timestamp":1603497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,24]],"date-time":"2020-10-24T00:00:00Z","timestamp":1603497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Valproate (VPA) is a commonly prescribed antiepileptic drug for patients experiencing epileptic seizures due to brain tumors. VPA increases radiation sensitivity in various tumor cells in vitro due to complex mechanisms. This could make tumors more vulnerable to ionizing radiation or overcome radioresistance. Yet, clinical data on possible improvement of tumor control by adding VPA to tumor therapy is controversial. Potentially radiosensitizing effects of VPA on healthy tissue remain unclear. To determine individual radiosensitivity, we analyzed blood samples of individuals taking VPA.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Ex vivo irradiated blood samples of 31 adult individuals with epilepsy were studied using 3-color fluorescence in situ hybridization. Aberrations in chromosomes 1, 2 and 4 were analyzed. Radiosensitivity was determined by the mean breaks per metaphase (B\/M) and compared to age-matched (2:1) healthy donors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The patient cohort (<jats:italic>n<\/jats:italic>\u2009=\u200931; female: 38.7%) showed an increase of their average B\/M value compared to healthy individuals (<jats:italic>n<\/jats:italic>\u2009=\u200961; female: 56.9%; B\/M: 0.480\u2009\u00b1\u20090.09 vs. 0.415\u2009\u00b1\u20090.07; <jats:italic>p<\/jats:italic>\u2009=\u2009.001). The portion of radiosensitive (B\/M\u2009&gt;\u2009\u00a00.500) and distinctly radiosensitive individuals (B\/M\u2009&gt;\u2009\u00a00.600) was increased in the VPA group (54.9% vs. 11.3 and 9.7% vs. 0.0%; <jats:italic>p<\/jats:italic>\u2009&lt;\u2009.001). In 3\/31 patients, radiosensitivity was determined prior to and after VPA treatment and radiosensitivity was increased by VPA-treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In our study, we confirmed that patients treated with VPA had an increased radiosensitivity compared to the control group. This could be considered in patients taking VPA prior to the beginning of radiotherapy to avoid toxic side effects of VPA-treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12883-020-01966-z","type":"journal-article","created":{"date-parts":[[2020,10,24]],"date-time":"2020-10-24T04:02:43Z","timestamp":1603512163000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Ex vivo radiosensitivity is increased in non-cancer patients taking valproate"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4888-6539","authenticated-orcid":false,"given":"Jenny","family":"Stritzelberger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Lainer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Gollwitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Graf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Jost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes D.","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara M.","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Schwab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Fietkau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajo M.","family":"Hamer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luitpold","family":"Distel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,24]]},"reference":[{"key":"1966_CR1","doi-asserted-by":"crossref","unstructured":"Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, Perez-Cardenas E, de la Cruz-Hernandez E, Herrera LA. Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev 2008;34(3):206\u2013222.","DOI":"10.1016\/j.ctrv.2007.11.003"},{"issue":"Suppl 1","key":"1966_CR2","first-page":"S91","volume":"83","author":"M Gottlicher","year":"2004","unstructured":"Gottlicher M. Valproic acid: an old drug newly discovered as inhibitor of histone deacetylases. Ann Hematol. 2004;83(Suppl 1):S91\u20132.","journal-title":"Ann Hematol"},{"issue":"2","key":"1966_CR3","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.canlet.2009.03.013","volume":"280","author":"N Batty","year":"2009","unstructured":"Batty N, Malouf GG, Issa JP. Histone deacetylase inhibitors as anti-neoplastic agents. Cancer Lett. 2009;280(2):192\u2013200.","journal-title":"Cancer Lett"},{"issue":"26","key":"1966_CR4","doi-asserted-by":"publisher","first-page":"4051","DOI":"10.1200\/JCO.2007.11.6202","volume":"25","author":"K Camphausen","year":"2007","unstructured":"Camphausen K, Tofilon PJ. Inhibition of histone deacetylation: a strategy for tumor radiosensitization. J Clin Oncol. 2007;25(26):4051\u20136.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1966_CR5","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1215\/15228517-2006-032","volume":"9","author":"M Entin-Meer","year":"2007","unstructured":"Entin-Meer M, Yang X, VandenBerg SR, Lamborn KR, Nudelman A, Rephaeli A, et al. In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas. Neuro-oncology. 2007;9(2):82\u20138.","journal-title":"Neuro-oncology."},{"key":"1966_CR6","doi-asserted-by":"crossref","unstructured":"Kalal BS, Pai VR, Behera SK, Somashekarappa HM. HDAC2 Inhibitor Valproic Acid Increases Radiation Sensitivity of Drug-Resistant Melanoma Cells. Med Sci (Basel). 2019;7(3).","DOI":"10.3390\/medsci7030051"},{"key":"1966_CR7","doi-asserted-by":"crossref","unstructured":"Liu G, Wang H, Zhang F, Tian Y, Tian Z, Cai Z, et al. The effect of VPA on increasing Radiosensitivity in osteosarcoma cells and primary-culture cells from chemical carcinogen-induced breast Cancer in rats. Int J Mol Sci. 2017;18(5).","DOI":"10.3390\/ijms18051027"},{"issue":"3","key":"1966_CR8","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1039\/C5TX00476D","volume":"5","author":"Y Luo","year":"2016","unstructured":"Luo Y, Wang H, Zhao X, Dong C, Zhang F, Guo G, et al. Valproic acid causes radiosensitivity of breast cancer cells via disrupting the DNA repair pathway. Toxicol Res. 2016;5(3):859\u201370.","journal-title":"Toxicol Res"},{"issue":"2","key":"1966_CR9","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s11060-014-1713-x","volume":"122","author":"AN Hosein","year":"2015","unstructured":"Hosein AN, Lim YC, Day B, Stringer B, Rose S, Head R, et al. The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells. J Neuro-Oncol. 2015;122(2):263\u201371.","journal-title":"J Neuro-Oncol"},{"issue":"33","key":"1966_CR10","doi-asserted-by":"publisher","first-page":"35004","DOI":"10.18632\/oncotarget.5253","volume":"6","author":"D Thotala","year":"2015","unstructured":"Thotala D, Karvas RM, Engelbach JA, Garbow JR, Hallahan AN, DeWees TA, et al. Valproic acid enhances the efficacy of radiation therapy by protecting normal hippocampal neurons and sensitizing malignant glioblastoma cells. Oncotarget. 2015;6(33):35004\u201322.","journal-title":"Oncotarget."},{"issue":"1","key":"1966_CR11","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s11060-011-0725-z","volume":"107","author":"KA Van Nifterik","year":"2012","unstructured":"Van Nifterik KA, Van den Berg J, Slotman BJ, Lafleur MV, Sminia P, Stalpers LJ. Valproic acid sensitizes human glioma cells for temozolomide and gamma-radiation. J Neuro-Oncol. 2012;107(1):61\u20137.","journal-title":"J Neuro-Oncol"},{"issue":"2","key":"1966_CR12","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.tranon.2016.12.011","volume":"10","author":"H Zhang","year":"2017","unstructured":"Zhang H, Zhang W, Zhou Y, Jiang Y, Li S. Dual functional Mesoporous silicon nanoparticles enhance the Radiosensitivity of VPA in Glioblastoma. Transl Oncol. 2017;10(2):229\u201340.","journal-title":"Transl Oncol"},{"issue":"39","key":"1966_CR13","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.18632\/oncotarget.26994","volume":"10","author":"MNA Kamarudin","year":"2019","unstructured":"Kamarudin MNA, Parhar I. Emerging therapeutic potential of anti-psychotic drugs in the management of human glioma: a comprehensive review. Oncotarget. 2019;10(39):3952\u201377.","journal-title":"Oncotarget."},{"issue":"1","key":"1966_CR14","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3892\/ol.2013.1666","volume":"7","author":"Y Zhou","year":"2014","unstructured":"Zhou Y, Xu Y, Wang H, Niu J, Hou H, Jiang Y. Histone deacetylase inhibitor, valproic acid, radiosensitizes the C6 glioma cell line in vitro. Oncol Lett. 2014;7(1):203\u20138.","journal-title":"Oncol Lett"},{"issue":"7","key":"1966_CR15","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1200\/JCO.2015.63.6563","volume":"34","author":"C Happold","year":"2016","unstructured":"Happold C, Gorlia T, Chinot O, Gilbert MR, Nabors LB, Wick W, et al. Does Valproic acid or Levetiracetam improve survival in Glioblastoma? A pooled analysis of prospective clinical trials in newly diagnosed Glioblastoma. J Clin Oncol. 2016;34(7):731\u20139.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1966_CR16","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1093\/nop\/npy009","volume":"5","author":"AV Krauze","year":"2018","unstructured":"Krauze AV, Mackey M, Rowe L, Chang MG, Holdford DJ, Cooley T, et al. Late toxicity in long-term survivors from a phase 2 study of concurrent radiation therapy, temozolomide and valproic acid for newly diagnosed glioblastoma. Neuro-oncol Pract. 2018;5(4):246\u201350.","journal-title":"Neuro-oncol Pract"},{"issue":"4","key":"1966_CR17","doi-asserted-by":"publisher","first-page":"e440","DOI":"10.18295\/squmj.2018.18.04.003","volume":"18","author":"A Aghamohammadi","year":"2018","unstructured":"Aghamohammadi A, Akrami SM, Yaghmaie M, Rezaei N, Azizi G, Yaseri M, et al. Individual Radiosensitivity assessment of the families of Ataxia-telangiectasia patients by G2-checkpoint abrogation. Sultan Qaboos Univ Med J. 2018;18(4):e440\u2013e6.","journal-title":"Sultan Qaboos Univ Med J"},{"issue":"6","key":"1966_CR18","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1093\/annonc\/mdv139","volume":"26","author":"M Hecht","year":"2015","unstructured":"Hecht M, Zimmer L, Loquai C, Weishaupt C, Gutzmer R, Schuster B, et al. Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients. Ann Oncol. 2015;26(6):1238\u201344.","journal-title":"Ann Oncol"},{"issue":"1","key":"1966_CR19","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s12883-016-0700-6","volume":"16","author":"H Ye","year":"2016","unstructured":"Ye H, Chen M, Cao F, Huang H, Zhan R, Zheng X. Chloroquine, an autophagy inhibitor, potentiates the radiosensitivity of glioma initiating cells by inhibiting autophagy and activating apoptosis. BMC Neurol. 2016;16(1):178.","journal-title":"BMC Neurol"},{"issue":"1","key":"1966_CR20","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/mpo.10275","volume":"41","author":"L Distel","year":"2003","unstructured":"Distel L, Neubauer S, Varon R, Holter W, Grabenbauer G. Fatal toxicity following radio- and chemotherapy of medulloblastoma in a child with unrecognized Nijmegen breakage syndrome. Med Pediatr Oncol. 2003;41(1):44\u20138.","journal-title":"Med Pediatr Oncol"},{"issue":"3","key":"1966_CR21","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.radonc.2006.10.012","volume":"81","author":"LV Distel","year":"2006","unstructured":"Distel LV, Neubauer S, Keller U, Sprung CN, Sauer R, Grabenbauer GG. Individual differences in chromosomal aberrations after in vitro irradiation of cells from healthy individuals, cancer and cancer susceptibility syndrome patients. Radiother Oncol. 2006;81(3):257\u201363.","journal-title":"Radiother Oncol"},{"issue":"1","key":"1966_CR22","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s00066-017-1207-9","volume":"194","author":"A Fahrig","year":"2018","unstructured":"Fahrig A, Koch T, Lenhart M, Rieckmann P, Fietkau R, Distel L, et al. Lethal outcome after pelvic salvage radiotherapy in a patient with prostate cancer due to increased radiosensitivity: case report and literature review. Strahlentherapie Onkologie. 2018;194(1):60\u20136.","journal-title":"Strahlentherapie Onkologie"},{"issue":"6","key":"1966_CR23","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s00066-019-01552-4","volume":"196","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Yan T, Zhou X, Cao P, Luo C, Zhou L, et al. Acute severe radiation pneumonitis among non-small cell lung cancer (NSCLC) patients with moderate pulmonary dysfunction receiving definitive concurrent chemoradiotherapy: impact of pre-treatment pulmonary function parameters. Strahlenther Onkol. 2020;196(6):505\u201314.","journal-title":"Strahlenther Onkol."},{"issue":"5","key":"1966_CR24","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00066-018-1401-4","volume":"195","author":"RJ Klement","year":"2019","unstructured":"Klement RJ, Sch\u00e4fer G, Sweeney RA. A fatal case of Fournier's gangrene during neoadjuvant radiotherapy for rectal cancer. Strahlenther Onkol. 2019;195(5):441\u20136.","journal-title":"Strahlenther Onkol"},{"issue":"1","key":"1966_CR25","doi-asserted-by":"publisher","first-page":"80","DOI":"10.2478\/raon-2013-0061","volume":"48","author":"J Auer","year":"2014","unstructured":"Auer J, Keller U, Schmidt M, Ott O, Fietkau R, Distel LV. Individual radiosensitivity in a breast cancer collective is changed with the patients' age. Radiol Oncol. 2014;48(1):80\u20136.","journal-title":"Radiol Oncol"},{"issue":"1","key":"1966_CR26","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12877-018-0799-y","volume":"18","author":"B Schuster","year":"2018","unstructured":"Schuster B, Ellmann A, Mayo T, Auer J, Haas M, Hecht M, et al. Rate of individuals with clearly increased radiosensitivity rise with age both in healthy individuals and in cancer patients. BMC Geriatr. 2018;18(1):105.","journal-title":"BMC Geriatr"},{"issue":"5","key":"1966_CR27","first-page":"2479","volume":"35","author":"J Linam","year":"2015","unstructured":"Linam J, Yang LX. Recent developments in radiosensitization. Anticancer Res. 2015;35(5):2479\u201385.","journal-title":"Anticancer Res"},{"issue":"2","key":"1966_CR28","first-page":"1728","volume":"15","author":"M Hecht","year":"2018","unstructured":"Hecht M, Harrer T, K\u00f6rber V, Sarpong EO, Moser F, Fiebig N, et al. Cytotoxic effect of Efavirenz in BxPC-3 pancreatic cancer cells is based on oxidative stress and is synergistic with ionizing radiation. Oncol Lett. 2018;15(2):1728\u201336.","journal-title":"Oncol Lett"},{"issue":"1","key":"1966_CR29","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1186\/s12885-020-07190-9","volume":"20","author":"V Weigert","year":"2020","unstructured":"Weigert V, Jost T, Hecht M, Knippertz I, Heinzerling L, Fietkau R, et al. PARP inhibitors combined with ionizing radiation induce different effects in melanoma cells and healthy fibroblasts. BMC Cancer. 2020;20(1):775.","journal-title":"BMC Cancer"},{"key":"1966_CR30","doi-asserted-by":"crossref","unstructured":"Dobler C, Jost T, Hecht M, Fietkau R, Distel L. Senescence induction by combined ionizing radiation and DNA damage response inhibitors in Head and neck squamous cell carcinoma cells. Cells. 2020;9(9).","DOI":"10.3390\/cells9092012"},{"issue":"5","key":"1966_CR31","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s00066-004-1200-y","volume":"180","author":"U Keller","year":"2004","unstructured":"Keller U, Kuechler A, Liehr T, Muller E, Grabenbauer G, Sauer R, et al. Impact of various parameters in detecting chromosomal aberrations by FISH to describe radiosensitivity. Strahlentherapie Onkologie. 2004;180(5):289\u201396.","journal-title":"Strahlentherapie Onkologie"},{"issue":"2","key":"1966_CR32","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S0167-8140(97)01932-4","volume":"43","author":"S Neubauer","year":"1997","unstructured":"Neubauer S, Dunst J, Gebhart E. The impact of complex chromosomal rearrangements on the detection of radiosensitivity in cancer patients. Radiother Oncol. 1997;43(2):189\u201395.","journal-title":"Radiother Oncol"},{"issue":"1","key":"1966_CR33","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/0027-5107(94)90308-5","volume":"307","author":"JR Savage","year":"1994","unstructured":"Savage JR, Simpson P. On the scoring of FISH-\u201cpainted\u201d chromosome-type exchange aberrations. Mutat Res. 1994;307(1):345\u201353.","journal-title":"Mutat Res"},{"issue":"12","key":"1966_CR34","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.3109\/09553002.2013.825060","volume":"89","author":"LA Beaton","year":"2013","unstructured":"Beaton LA, Marro L, Samiee S, Malone S, Grimes S, Malone K, et al. Investigating chromosome damage using fluorescent in situ hybridization to identify biomarkers of radiosensitivity in prostate cancer patients. Int J Radiat Biol. 2013;89(12):1087\u201393.","journal-title":"Int J Radiat Biol"},{"issue":"2","key":"1966_CR35","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.radonc.2003.10.001","volume":"69","author":"U Hoeller","year":"2003","unstructured":"Hoeller U, Borgmann K, Bonacker M, Kuhlmey A, Bajrovic A, Jung H, et al. Individual radiosensitivity measured with lymphocytes may be used to predict the risk of fibrosis after radiotherapy for breast cancer. Radiother Oncol. 2003;69(2):137\u201344.","journal-title":"Radiother Oncol"},{"issue":"2","key":"1966_CR36","doi-asserted-by":"publisher","first-page":"155","DOI":"10.5114\/ceji.2018.77385","volume":"43","author":"M Mahmoodi","year":"2018","unstructured":"Mahmoodi M, Abolhassani H, Mozdarani H, Rezaei N, Azizi G, Yazdani R, et al. In vitro chromosomal radiosensitivity in patients with common variable immunodeficiency. Central Eur J Immunol. 2018;43(2):155\u201361.","journal-title":"Central Eur J Immunol"},{"issue":"5","key":"1966_CR37","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s000660050005","volume":"176","author":"D Scott","year":"2000","unstructured":"Scott D. Chromosomal radiosensitivity, cancer predisposition and response to radiotherapy. Strahlentherapie Onkologie. 2000;176(5):229\u201334.","journal-title":"Strahlentherapie Onkologie"},{"issue":"10","key":"1966_CR38","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/BF03038983","volume":"174","author":"J Dunst","year":"1998","unstructured":"Dunst J, Neubauer S, Becker A, Gebhart E. Chromosomal in-vitro radiosensitivity of lymphocytes in radiotherapy patients and AT-homozygotes. Strahlentherapie Onkologie. 1998;174(10):510\u20136.","journal-title":"Strahlentherapie Onkologie"},{"issue":"5","key":"1966_CR39","doi-asserted-by":"publisher","first-page":"e0127142","DOI":"10.1371\/journal.pone.0127142","volume":"10","author":"M Brand","year":"2015","unstructured":"Brand M, Sommer M, Ellmann S, Wuest W, May MS, Eller A, et al. Influence of different antioxidants on X-ray induced DNA double-Strand breaks (DSBs) using gamma-H2AX immunofluorescence microscopy in a preliminary study. PLoS One. 2015;10(5):e0127142.","journal-title":"PLoS One"},{"issue":"3\u20134","key":"1966_CR40","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1177\/0146645318764091","volume":"47","author":"P Rajaraman","year":"2018","unstructured":"Rajaraman P, Hauptmann M, Bouffler S, Wojcik A. Human individual radiation sensitivity and prospects for prediction. Ann ICRP. 2018;47(3\u20134):126\u201341.","journal-title":"Ann ICRP"},{"issue":"3","key":"1966_CR41","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1080\/088800102753541314","volume":"19","author":"RY Tamminga","year":"2002","unstructured":"Tamminga RY, Dolsma WV, Leeuw JA, Kampinga HH. Chemo- and radiosensitivity testing in a patient with ataxia telangiectasia and Hodgkin disease. Pediatr Hematol Oncol. 2002;19(3):163\u201371.","journal-title":"Pediatr Hematol Oncol"},{"issue":"5","key":"1966_CR42","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.ijrobp.2015.04.038","volume":"92","author":"AV Krauze","year":"2015","unstructured":"Krauze AV, Myrehaug SD, Chang MG, Holdford DJ, Smith S, Shih J, et al. A phase 2 study of concurrent radiation therapy, Temozolomide, and the histone Deacetylase inhibitor Valproic acid for patients with Glioblastoma. Int J Radiat Oncol Biol Phys. 2015;92(5):986\u201392.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"1966_CR43","doi-asserted-by":"publisher","first-page":"463","DOI":"10.7314\/APJCP.2016.17.2.463","volume":"17","author":"S Ochiai","year":"2016","unstructured":"Ochiai S, Nomoto Y, Yamashita Y, Watanabe Y, Toyomasu Y, Kawamura T, et al. Roles of Valproic acid in improving radiation therapy for Glioblastoma: a review of literature focusing on clinical evidence. Asian Pac J Cancer Prev. 2016;17(2):463\u20136.","journal-title":"Asian Pac J Cancer Prev"},{"key":"1966_CR44","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.3389\/fphar.2019.01262","volume":"10","author":"C Zhuo","year":"2019","unstructured":"Zhuo C, Xun Z, Hou W, Ji F, Lin X, Tian H, et al. Surprising anticancer activities of psychiatric medications: old drugs offer new Hope for patients with brain Cancer. Front Pharmacol. 2019;10:1262.","journal-title":"Front Pharmacol"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-020-01966-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-020-01966-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-020-01966-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,23]],"date-time":"2021-10-23T19:06:42Z","timestamp":1635016002000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-020-01966-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,24]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1966"],"URL":"https:\/\/doi.org\/10.1186\/s12883-020-01966-z","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,24]]},"assertion":[{"value":"9 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the ethics review committee of the Friedrich-Alexander-Universitaet Erlangen-Nuernberg (No. 21_19B). Written informed consent was obtained from all the patients.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"WG received a lecture fee from UCB and Desitin. HH reports personal fees from UCB, personal fees from Desitin, personal fees from Eisai, personal fees from GW, personal fees from Novartis, personal fees from IQWiG, personal fees from Hexal, personal fees from facetoface, grants from Amgen, Ad-Tech, Bracco, Pfizer, Micromed, Nihon Kohden, personal fees from Arvelle, outside the submitted work. The other authors have nothing to report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"390"}}